Virtual Reality Headset
DeviceUse of a virtual reality headset during rectosigmoidoscopy
NCT Number: NCT06632691
Haemorrhagic rectocolitis is an inflammatory bowel disease that continuously affects the rectum and colon, with lesions that extend variably from the rectum into the upstream colon. This disease requires repeated assessment of both clinical activity (transcribed by the clinical Mayo score) and endoscopic activity. ACCEPT study showed that the acceptability of rectosigmoidoscopy is low, and the main determinants of this low acceptability were pain and bloating (51%) and embarrassment during the examination (30%).
Virtual reality headsets has analgesic and anxiolytic properties, thanks to specially designed virtual environments that apply different principles such as medical hypnosis, music therapy and cardiac coherence to enhance therapeutic action.
The aim of our project is to study the benefit of medical hypnosis provided by the use of a virtual reality headset in terms of tolerance of lower digestive endoscopy in patients with ulcerative colitis.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France
Haemorrhagic rectocolitis is an inflammatory bowel disease that continuously affects the rectum and colon, with lesions that extend variably from the rectum into the upstream colon.
This disease requires repeated assessment of both clinical activity (transcribed by the clinical Mayo score) and endoscopic activity. Assessment of mucosal healing is one of the therapeutic objectives defined in the STRIDE II consensus, and requires regular repeat endoscopic examinations in these patients.
The aim of the ACCEPT study, which involved administering a questionnaire to 916 patients with chronic inflammatory bowel disease, was to assess patients; acceptability and perceived usefulness of examinations designed to assess the activity of chronic inflammatory bowel disease. This study showed that the acceptability of rectosigmoidoscopy is low, and the main determinants of this low acceptability were pain and bloating (51%) and embarrassment during the examination (30%).
The dominant approaches to addressing this issue focus on replacing rectosigmoidoscopy with less invasive tools such as ultrasound and faecal calprotectin. However, rectosigmoidoscopy is still unavoidable, particularly for rectal forms (poor performance of ultrasound, low reliability of faecal calprotectin).
Virtual reality headsets are now part of our everyday lives. Developed as part of the neurosciences, they have applications in healthcare (pain care, dementia, post-traumatic stress disorder, etc.), occupational risk prevention and leisure (escape games, video games).
This device has analgesic and anxiolytic properties, thanks to specially designed virtual environments that apply different principles such as medical hypnosis, music therapy and cardiac coherence to enhance therapeutic action.
This approach has been evaluated in endoscopy, to improve the tolerance of colorectal cancer screening colonoscopies. A Chinese study (Liu et al, Clinical medicine 2022), which included 120 patients in a randomised trial comparing the virtual reality headset with a headset that was switched off, showed that the headset that was switched on made it possible to gain a median of 2 points on the pain scale, to reduce skin conductance (an indirect marker of nervousness) and to improve patient satisfaction. We hypothesise that the gain in SR would be the same, with an examination that is reputed to be less painful than colonoscopy without anaesthetic.
The aim of our project is to study the benefit of medical hypnosis provided by the use of a virtual reality headset in terms of tolerance of lower digestive endoscopy in patients with ulcerative colitis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of a virtual reality headset during rectosigmoidoscopy
Time frame: Immediately after the examination.
Pain intensity measured on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (maximum intolerable pain) immediately after the examination.
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Departemental Vendee
Other
Acronym: VIRTU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.